Skip to content
    BCRX
    Earnings call· Jun 2026(Q2 FY26)

    BIOCRYST PHARMACEUTICALS Q2 FY26 earnings call BCRX

    Aug 5, 2026 Source

    Executive summary

    BioCryst Q2 FY26 — Strong ORLADEYO Performance & Strategic Shift to External Innovation

    BioCryst Pharmaceuticals delivered a strong Q2 FY26, driven by robust ORLADEYO performance and a significant upfront payment from a navenibart licensing deal. The company is strategically shifting its R&D focus to external innovation, aiming to build a balanced pipeline of rare disease assets while maintaining a strong financial position. Key clinical programs, including navenibart and BCX17725, are advancing as planned, with the pediatric ORLADEYO launch exceeding early expectations.

    Highlights

    5

    • Total revenue increased 45% year-on-year on a comparable basis, reaching $213.9 million.

    • ORLADEYO revenue grew 10% year-on-year on a comparable basis to $158.2 million.

    • Non-GAAP operating profit was strong at $113.2 million for the quarter.

    • ORLADEYO oral pellets received 47 prescriptions through July 31, well ahead of 2026 expectations.

    • Ended the quarter with just over $350 million in cash, cash equivalents, and investments, generating positive cash flow even without license proceeds.

    Concerns

    1

    • The ORLADEYO paid rate typically drops by 1-2 percentage points in the second half of the year due to a changing patient mix.

    Guidance & targets

    5
    CategoryTargetConfidence
    Total revenue
    $690 million to $715 million
    high materiality
    High
    ORLADEYO revenue
    $625 million to $645 million
    high materiality
    High
    Non-GAAP operating costs
    $420 million to $440 million
    medium materiality
    High
    Navenibart top-line data
    Q3 2027
    high materiality
    High
    BCX17725 Netherton syndrome data
    by the end of the year
    medium materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    ORLADEYO
    ORLADEYO continues to demonstrate strong commercial performance, with consistent demand for capsules and a successful early launch of the pediatric oral pellets. The improved paid rate reflects effective management of reimbursement. New injectables primarily impact existing injectable competitors, not ORLADEYO persistence.
    New prescriptions for capsules: consistent with historical expectationsNew prescribers: in line with historical trends (approx. 60/month)Paid rate: 84% (vs 83% 1 year ago)ORLADEYO oral pellets prescriptions (through July 31): 47ORLADEYO oral pellets prior authorizations: ~50% completeORLADEYO oral pellets approval rate: strongOverall retention for ORLADEYO: same pattern as past trendsVolume growth contribution to revenue: ~50%Price/reimbursement contribution to revenue: ~50%Patients on therapy: 1,600Patients tried product since launch: 3,500Estimated diagnosed pediatric HAE patients: 500Estimated potential pediatric HAE patients: 1,200
    		$158.2 million10%——

    Operational metrics

    6
    Total revenue (comparable basis)
    $213.9 millionup 45% YoY
    Q2 FY26

    Excluding the European divestiture. Includes $55.7 million recognized from the navenibart European license agreement.

    Non-GAAP operating profit
    $113.2 million
    Q2 FY26

    Adjusted for revenues and expenses related to former European ORLADEYO business, stock-based compensation, and Astria acquisition expenses.

    Cash, cash equivalents and investments
    just over $350 million
    Q2 FY26 end

    Balance sheet in excellent shape; generated positive cash flow in the quarter even setting aside upfront license proceeds.

    Non-GAAP G&A expense
    relatively flatcompared to prior periods
    Q2 FY26 and 6-month period

    Reflects stable operating costs across the business.

    Non-GAAP Sales and Marketing expense
    relatively flatcompared to prior periods
    Q2 FY26 and 6-month period

    Reflects stable operating costs across the business.

    Non-GAAP R&D expense
    increase
    Q2 FY26

    Driven by ongoing Phase III activities for navenibart.

    Industry KPIs

    6
    MetricValueDetails
    Launch access metrics84%%
    Pipeline read out calendarTop-line data expected
    Product franchise net sales$158.2 millionUSD
    Prescription volume new starts47prescriptions
    Collaboration milestone royalty revenue$55.7 millionUSD
    Cumulative patients uptake since launch1,600patients

    Product announcements

    1
    ProductTypeDetails
    ORLADEYO oral pelletslaunch

    Deals & partnerships

    2
    Neopharmed GentiliEuropean license agreement for navenibart$55.7 million

    Upfront payment recognized in the quarter.

    CareMedNew sole-source pharmacy for ORLADEYO shipments

    CareMed was chosen for its ability to scale operations and experience with prophylactic programs. All ORLADEYO pellets prescriptions are shipping from CareMed, and the 12 and up population will transition over the course of August 2026.

    Risks & headwinds

    3
    Competitive pressure from new injectable HAE prophylactic productsOngoing

    New injectables are primarily affecting existing injectables, particularly TAKHZYRO, rather than ORLADEYO persistence.

    Mitigation: ORLADEYO retention remains stable, and market research shows continued preference and satisfaction among patients and physicians.

    Potential for ORLADEYO paid rate to drop in second half of yearH2 FY26

    Typically 1-2 percentage points lost over the second half of the year.

    Mitigation: This is due to a patient mix driven more by new patients. The company expects to regain this in the next year's reauthorization season, with a long-term goal of 85%.

    Transition to new sole-source pharmacy (CareMed)Starting August 2026

    Potential for 'bumps' during the transition period.

    Mitigation: While short-term issues may arise, the transition is not expected to affect ORLADEYO long-term, as CareMed was selected for its ability to scale and experience with prophylactic programs.

    What to watch in Q3 FY26

    4

    ORLADEYO oral pellets prescription rates

    Next quarter
    Current47 prescriptions through July 31
    TargetOngoing trend and growth

    Why it matters

    This indicates the real-world uptake and market expansion potential of the pediatric formulation, which is a new growth driver for the company.

    We have a lot to learn about ongoing prescription rates, rates of paid therapy and real world outcomes for kids taking ORLADEYO, but we are thrilled to be delivering this much-needed therapy.

    Q&A highlights

    6

    Are new injectable HAE prophylactic products impacting ORLADEYO persistence? How is enrollment for the Netherton program, and what have been the learnings?

    ORLADEYO's retention pattern remains stable, with new injectables primarily affecting existing injectable competitors like TAKHZYRO. Enrollment for the Netherton trial is on track for data by year-end, with good safety and drug distribution observed in earlier healthy volunteer data.

    “what we're seeing is what we expected from all of our market research is that the injectables are primarily affecting existing injectables, particularly TAKHZYRO.”

    asked by Laura Chico · answered by Charles Gayer

    2 min read6 chapters

    Detailed Narrative

    01

    ORLADEYO Commercial Performance

    ORLADEYO demonstrated continued strong demand in Q2 FY26, with new prescriptions for capsules consistent with historical expectations and new prescribers added at a rate in line with historical trends (approximately 60 per month). The paid rate for ORLADEYO improved to 84% at quarter-end, up from 83% a year ago, reflecting ongoing efforts in reauthorization. The pediatric oral pellets launched successfully, garnering 47 prescriptions through July 31, significantly exceeding initial expectations for the entire year.

    02

    Strategic Shift to External Innovation

    BioCryst has made a strategic decision to discontinue internal drug discovery programs and close its Birmingham research unit by year-end. This shift aims to reallocate resources towards external innovation, allowing the company to build a more balanced pipeline of differentiated rare disease assets across various clinical stages. The new strategy focuses on leveraging BioCryst's scientific, clinical, and commercial strengths in areas of high unmet medical need, with an emphasis on clinical-stage assets.

    03

    Navenibart Clinical Progress

    Enrollment for the pivotal ALPHA-ORBIT study of navenibart, an investigational long-acting injectable plasma kallikrein inhibitor for HAE prophylaxis, was completed ahead of schedule in June 2026. This study represents the largest blinded HAE trial ever conducted. Top-line data for navenibart is anticipated in the third quarter of 2027. The study will remain blinded to collect one year of safety and efficacy data, as agreed with the FDA, to evaluate efficacy at both 6 and 12 months for its extended dosing regimen.

    04

    Netherton Syndrome Program (BCX17725)

    The proof-of-concept trial for BCX17725 in Netherton syndrome is enrolling well, with early clinical data from Part 4 of the Phase Ib study expected by the end of 2026. BCX17725 is a targeted drug for Netherton syndrome, impacting the implicated KLK5 enzyme, and has shown good tolerability in healthy volunteers. Management believes it has the potential to be the first systemically administered and targeted treatment for this rare, severe skin condition, which currently has no approved therapies.

    05

    Financial Strength and Capital Allocation

    BioCryst reported a strong non-GAAP operating profit of $113.2 million for the quarter and ended with over $350 million in cash, cash equivalents, and investments. The company generated positive cash flow in the quarter, even excluding the upfront proceeds from the navenibart license agreement. The strategic shift to external innovation is expected to generate meaningful cost savings, contributing to a leaner operating model. BioCryst is committed to delivering profitable growth and maintaining flexibility for business development, deleveraging, or share buybacks without stressing its balance sheet.

    06

    Specialty Pharmacy Transition

    BioCryst has partnered with CareMed as its new sole-source pharmacy for ORLADEYO shipments to patients. This decision was driven by CareMed's ability to scale operations to support BioCryst's growing HAE portfolio and patient base. All ORLADEYO pellets prescriptions for kids are already shipping from CareMed, and the transition for the 12 and up population will occur throughout August 2026. While potential short-term 'bumps' during the transition are acknowledged, the move is expected to be beneficial long-term for patients.

    AI-generated summary of the company’s earnings call. Not investment advice.